Core Insights - IDEAYA Biosciences, Inc. is a precision medicine oncology company focused on developing targeted therapeutics for specific patient populations using molecular diagnostics [1] - The company has promising product candidates, including IDE397 and IDE196, currently in various stages of clinical trials, alongside a strong preclinical pipeline targeting synthetic lethality programs [1] Price Target Trends - The consensus price target for IDEAYA Biosciences has fluctuated, decreasing from an average of $54.67 a quarter ago to $45 in the past month, which is similar to the target from a year ago at $44 [2] - Analysts from Robert W. Baird have set a price target of $18, reflecting the potential of the company's extensive portfolio and near-term catalysts [5] Lead Asset and Revenue Potential - The lead asset, darovasertib, is aimed at treating uveal melanoma and has shown promising results in Phase 2 trials, with potential peak revenue exceeding $500 million [3] - The success of darovasertib could significantly impact the company's financial performance and stock valuation [3] Strategic Partnerships - IDEAYA has established strong partnerships, including one with Servier and collaborations with major pharmaceutical companies like GlaxoSmithKline plc, which are crucial for accelerating drug development [4] - These partnerships may influence analyst sentiment and price targets moving forward [4]

Core Insights - IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is recognized as a promising healthcare stock with significant upside potential, supported by recent analyst ratings [1][2] - The company is focused on oncology and precision medicine, particularly through its lead asset, darovasertib, which targets uveal melanoma [3][4] Group 1: Analyst Ratings - Citizens JMP analyst Silvan Tuerkcan maintained a Buy rating for IDEAYA with a price target of $45 [1] - J.P. Morgan analyst Anupam Rama also assigned a Buy rating with a higher price target of $74 [2] Group 2: Product Development - IDEAYA's lead asset, darovasertib, is expected to have notable updates in various treatment settings, which could lead to significant value creation [3] - The company is developing IDE196, a protein kinase C inhibitor aimed at genetically defined cancers with GNAQ or GNA11 gene mutations [4]

Group 1 - IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is recognized as a promising biotech stock with high potential, receiving a Buy rating from J.P. Morgan analyst Anupam Rama with a price target of $74 [1] - The bullish rating is supported by anticipated updates on the company's lead asset, darovasertib, which is expected to create significant value [2] - UBS analyst David Dai also reiterated a Buy rating for IDEAYA Biosciences with a price target of $50, highlighting the company's focus on oncology precision medicine and targeted therapeutics [3] Group 2 - IDEAYA's product candidate, IDE196, is a protein kinase C inhibitor targeting genetically defined cancers associated with GNAQ or GNA11 gene mutations [3]